Biomedicine

Disease biomarkers: What's the risk?

+ See all authors and affiliations

Science  07 Nov 2014:
Vol. 346, Issue 6210, pp. 713
DOI: 10.1126/science.346.6210.713-a
CREDIT: MEDICALRF/SCIENCE SOURCE

With approximately 60% of cardiac events occurring in patients of low or moderate risk, doctors need new biomarkers to accurately predict which of their patients will develop disease. Antibodies targeting the protein apolipoprotein A-1 (apoA-1), which plays a role in lipid metabolism, are one such candidate. Some of these antibodies may confer more risk than others, depending where on apoA-1 they bind. Using serum samples from cardiac patients, Teixeira et al. identified the peptides within apoA-1 where antibodies bound. These finding may point toward new therapeutic opportunities and improved biomarkers for predicting the risk of cardiovascular disease.

J. Biol. Chem. 10.1074/jbc.M114.589002 (2014).

Navigate This Article